Pelobiomed-Tron Announces Board Approval of Q1 115 Consolidated Financial Statements

1. Date of submission to or resolution by the board of directors: 115/05/05 2. Date of approval by the audit committee: 115/05/05 3. Reporting period of financial report or self-compiled financial information (YYY/MM/DD~YYY/MM/DD): 115/01/01~115/03/31 4. Cumulative operating revenue from January 1 to current period (in thousands of NTD): 6,368 5. Cumulative operating gross profit (loss) from January 1 to current period (in thousands of NTD): (1,205) 6. Cumulative operating income (loss) from January 1 to current period (in thousands of NTD): (88,755) 7. Cumulative net profit (loss) before tax from January 1 to current period (in thousands of NTD): (87,174) 8. Cumulative net profit (loss) for the current period from January 1 to current period (in thousands of NTD): (87,174) 9. Cumulative net profit (loss) attributable to owners of the parent from January 1 to current period (in thousands of NTD): (76,584) 10. Cumulative basic earnings (loss) per share from January 1 to current period (in NTD): (1.18) 11. Total assets at period-end (in thousands of NTD): 3,291,024 12. Total liabilities at period-end (in thousands of NTD): 368,950 13. Equity attributable to owners of the parent at period-end (in thousands of NTD): 2,660,599 14. Other matters that should be specified: None